know boy time fetch increas pt
invest summari posit top-lin result compani pilot
effect studi reiter overweight rate rais
price target target-price increas driven
increas convict antibodi pipelin includ
fulli canin high-affin monoclon antibodi treatment atop
dermat dog product like readout earli
number undisclos antibodi product compani work
yet disclos believ pipelin novel anim health drug drive
long-term sharehold valu expect upward earn revis multipl
expans pipelin advanc drive stock higher
announc posit pilot data compani
first antibodi product valid abil develop portfolio
companion anim antibodi product target larg market opportun
differenti superior product multipl antibodi product
candid develop could repres opportun
support thesi stock continu offer investor
 move ahead faster expect competit reason
today data releas limit top-lin readout compani disclos
statist signific reduct pruritu
achiev across dose group sustain week clear
dose respons reduct itch score high although
limit data releas publicli alreadi initi pilot field studi
view today data compel enough wait
readout advanc
build robust data packag submiss creat multipl data readout
antibodi pipelin product support
continu momentum stock need run pivot studi
believ similar endpoint ow cover
louis chen cytopoint think today readout make even-
attract asset complement larger anim health compani portfolio
 atop dermat market larg grow space multipl
blockbust atop dermat market lucr anim
health compani to-dat believ market suffici capac
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
kindr current one approv product mirataz sale mirataz
expect may hamper compani abil meet expect financ
kindr depend substanti success pipelin may receiv regulatori
approv unit state europ
posit studi trial result obtain to-dat may disput fda review guarante
regulatori approv may obtain futur clinic trial
kindr need addit capit pursu commerci product
candid uptak mirataz remain pipelin forecast
lack new product launch and/or exist product fail gain market share street
good expect kindr new launch compani perform line
better expect could downsid risk number
macro factor could advers affect sale earn
brand gener compound product competit key drug kindr face competit
could headwind sale given limit number product pipelin
unforeseen competit one key product could meaning affect compani
abil meet expect rais capit need kindr pipelin
product compani abl bring market allevi risk
exhibit catalyst event calendar
datedriverupcom oralsubmit sectionl ivapprovalearli efficaci resultsearli efficaci pivot pivot dermat antibodybegin pivot eu approv approvalstwo product approv per dermat cantor fitzgerald research compani report exhibit incom statement analysi
million compound-annual-growth-rate year end decemb revenu oper share chang yoytot cantor fitzgerald research compani report exhibit margin analysi
revenu cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb fever equin gastric equin metabol antibodi sick antibodi ib product agreement chang fever equin gastric equin metabol antibodi sick foalsnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmanti-tnf antibodi ib dogsnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmothernmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmtot product agreement revenuenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmcontract revenuenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmothernmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmtot cantor fitzgerald research compani report exhibit annual sale analysi
 fever equin gastric equin metabol antibodi sick antibodi ib product agreement cantor fitzgerald research compani reportsyear end decemb exhibit analysi
million year end decemb flow provid oper activ net depreci net chang work net cash provid oper flow invest activitiespurchas pp capit net proce sale acquisit net cash acquired- other- net cash use invest flow financ activ repay issuanc long term debt- proce issuanc other- net cash use provid financ net decreas increas cash equival begin equival end sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million year end decemb account receiv less allow doubt accounts- inventories- current total current plant properti identifi intangibles- goodwill- total total liabil sharehold equityaccount payabl accru total current long term debt total sharehold total stockhold non-controlling interest- total liabil stockhold sourc cantor fitzgerald research compani report octob
companion anim health compani focus bring small molecul monoclon antibodi product
market kindr target therapi within canin felin equin companion anim market kindr approach drug develop
target molecul known work human repurpos molecul appli pet reduc technic risk time
involv drug develop compani first product approv year mirataz expect second approv
end year two approv per year thereaft
